# OH Beteiligungen

> OH Beteiligungen is a VC fund in Baden backing Medical, Therapeutics and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Baden, Germany
- Total investments: 3
- Last investment: Feb 2007
- Lead investor: 33%
- Last updated: Aug 2026

OH Beteiligungen is a German-based venture capital firm specialized in early stage investments.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Therapeutics | 1 | 33% |
| Biotechnology | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| immatics biotechnologies | immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy. immatics has a good track record of success: They are optimistic that they have found a way to develop drugs against cancer that might one day help many cancer patients. The product candidates are designed to have less severeside effects than currently available treatment options. immatics has developed peptide-based active immunotherapy with unprecedented speed and efficiency, setting new standards for discovery and development in this area of oncology drug development. Our technology can also lead towards the development of novel immunotherapies based on antibodies and T-cell receptors. immatics is currently working on the development of new substances for a number of specific cancer types. Their most advanced product is currently being developed in a phase 3 clinical trial for kidney cancer. Final results for this trial are expected in 2015. A second product targeting colorectal cancer has just completed a large phase 1/2 clinical trial and a third cancer vaccine has entered several phase 1 clinical trials in brain cancer. They also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer which are being developed in collaboration with our partner Roche. | $43.9M | Series B | Feb 08, 2007 |  |
| CureVac | CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.mRNA programs include novelmRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer. | $28.3M | Series B | Jan 18, 2006 |  |
| CureVac | CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.mRNA programs include novelmRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer. | $3M | Series A | Jan 01, 2003 |  |

3 of 3 investments shown.

## Co-investors
- [DH Capital](https://shizune.co/investors/profile/dh-capital) — VC Fund, 3 deals together
- [3i Group](https://shizune.co/investors/profile/3i-group) — VC Fund, 1 deal together
- [KfW](https://shizune.co/investors/profile/kfw) — VC Fund, 1 deal together
- [NTEC](https://shizune.co/investors/profile/ntec) — VC Fund, 1 deal together
- [Swisscom Ventures](https://shizune.co/investors/profile/swisscom-ventures) — VC Fund, 1 deal together
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does OH Beteiligungen invest in?

OH Beteiligungen invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Series B stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did OH Beteiligungen last invest?

The most recent investment recorded for OH Beteiligungen closed in Feb 2007. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co